Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a lung drug help COVID survivors breathe easier?

NCT ID NCT04619680

First seen May 07, 2026 · Last updated May 20, 2026 · Updated 2 times

Summary

This study tested whether the drug nintedanib can slow lung scarring in people who had COVID-19 and still have lung problems more than 30 days later. 103 adults who needed oxygen or had low oxygen levels took part. The goal was to see if the drug helps preserve lung function over 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Baylor University Medical Center Dallas

    Dallas, Texas, 75246, United States

  • Emory Healthcare Network

    Atlanta, Georgia, 30322, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Mount Sinai Beth Israel

    New York, New York, 10003, United States

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • University of Utah

    Salt Lake City, Utah, 84108, United States

Conditions

Explore the condition pages connected to this study.